{"doc_id": "33798499", "type of study": "Therapy", "title": "", "abstract": "Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.\nA new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020.\nWe report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant.\nVolunteers (aged \u226518 years) who were enrolled in phase 2/3 vaccine efficacy studies in the UK, and who were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 or a meningococcal conjugate control (MenACWY) vaccine, provided upper airway swabs on a weekly basis and also if they developed symptoms of COVID-19 disease (a cough, a fever of 37\u00b78\u00b0C or higher, shortness of breath, anosmia, or ageusia).\nSwabs were tested by nucleic acid amplification test (NAAT) for SARS-CoV-2 and positive samples were sequenced through the COVID-19 Genomics UK consortium.\nNeutralising antibody responses were measured using a live-virus microneutralisation assay against the B.1.1.7 lineage and a canonical non-B.1.1.7 lineage (Victoria).\nThe efficacy analysis included symptomatic COVID-19 in seronegative participants with a NAAT positive swab more than 14 days after a second dose of vaccine.\nParticipants were analysed according to vaccine received.\nVaccine efficacy was calculated as 1\u2009-\u2009relative risk (ChAdOx1 nCoV-19 vs MenACWY groups) derived from a robust Poisson regression model.\nThis study is continuing and is registered with ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137.\nParticipants in efficacy cohorts were recruited between May 31 and Nov 13, 2020, and received booster doses between Aug 3 and Dec 30, 2020.\nOf 8534 participants in the primary efficacy cohort, 6636 (78%) were aged 18-55 years and 5065 (59%) were female.\nBetween Oct 1, 2020, and Jan 14, 2021, 520 participants developed SARS-CoV-2 infection.\n1466 NAAT positive nose and throat swabs were collected from these participants during the trial.\nOf these, 401 swabs from 311 participants were successfully sequenced.\nLaboratory virus neutralisation activity by vaccine-induced antibodies was lower against the B.1.1.7 variant than against the Victoria lineage (geometric mean ratio 8\u00b79, 95% CI 7\u00b72-11\u00b70).\nClinical vaccine efficacy against symptomatic NAAT positive infection was 70\u00b74% (95% CI 43\u00b76-84\u00b75) for B.1.1.7 and 81\u00b75% (67\u00b79-89\u00b74) for non-B.1.1.7 lineages.\nChAdOx1 nCoV-19 showed reduced neutralisation activity against the B.1.1.7 variant compared with a non-B.1.1.7 variant in vitro, but the vaccine showed efficacy against the B.1.1.7 variant of SARS-CoV-2.\nUK Research and Innovation, National Institute for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midlands NIHR Clinical Research Network, and AstraZeneca.\nCopyright \u00a9 2021 The Author(s).\nPublished by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.\nPublished by Elsevier Ltd.. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "SARS-CoV-2 variant of concern", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 85}, {"term": "01", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 91}, {"term": "COVID-19 disease", "negation": "affirmed", "UMLS": {}, "start": 310, "end": 326}, {"term": "cough", "negation": "affirmed", "UMLS": {}, "start": 331, "end": 336}, {"term": "fever", "negation": "affirmed", "UMLS": {}, "start": 341, "end": 346}, {"term": "SARS-CoV-2", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 76}, {"term": "symptomatic COVID-19", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 51}, {"term": "seronegative", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 67}, {"term": "NAAT positive swab", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 106}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Efficacy of ChAdOx1 nCoV-19 ( AZD1222 ) vaccine against SARS-CoV-2 variant of concern 202012 / 01 ( B.1.1.7 ) : an exploratory analysis of a randomised controlled trial .", "Evidence Elements": {"Participant": [{"term": "SARS-CoV-2 variant of concern", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 85}, {"term": "01", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 91}], "Intervention": [{"term": "ChAdOx1 nCoV-19 ( AZD1222 ) vaccine", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 47, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 16, "end": 23, "has_count": ["19"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "A new variant of SARS-CoV-2 , B.1.1.7 , emerged as the dominant cause of COVID-19 disease in the UK from November , 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine , ChAdOx1 nCoV-19 ( AZD1222 ) , against this variant .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "adenoviral vector vaccine", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 78, "has_chemical": [{"text": "adenoviral vector vaccine", "maps_to": "C0597641:vector vaccine", "start": 0, "end": 25}], "has_relation": "N/A"}, {"term": "ChAdOx1 nCoV-19 ( AZD1222 )", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 108, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Volunteers ( aged \u226518 years ) who were enrolled in phase 2 / 3 vaccine efficacy studies in the UK , and who were randomly assigned ( 1:1 ) to receive ChAdOx1 nCoV-19 or a meningococcal conjugate control ( MenACWY ) vaccine , provided upper airway swabs on a weekly basis and also if they developed symptoms of COVID-19 disease ( a cough , a fever of 37\u00b78 ##\u00b0C or higher , shortness of breath , anosmia , or ageusia ) .", "Evidence Elements": {"Participant": [{"term": "COVID-19 disease", "negation": "affirmed", "UMLS": {}, "start": 310, "end": 326}, {"term": "cough", "negation": "affirmed", "UMLS": {}, "start": 331, "end": 336}, {"term": "fever", "negation": "affirmed", "UMLS": {}, "start": 341, "end": 346}], "Intervention": [{"term": "ChAdOx1 nCoV-19", "negation": "affirmed", "UMLS": {}, "start": 150, "end": 165, "has_relation": "N/A"}, {"term": "meningococcal conjugate control ( MenACWY ) vaccine", "negation": "affirmed", "UMLS": {}, "start": 171, "end": 222, "has_chemical": [{"text": "meningococcal conjugate", "maps_to": "C0915344:meningococcal C conjugate", "start": 0, "end": 23}, {"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 32, "end": 39}], "has_relation": "N/A"}], "Outcome": [{"term": "symptoms", "negation": "affirmed", "UMLS": {}, "start": 298, "end": 306}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Swabs were tested by nucleic acid amplification test ( NAAT ) for SARS-CoV-2 and positive samples were sequenced through the COVID-19 Genomics UK consortium .", "Evidence Elements": {"Participant": [{"term": "SARS-CoV-2", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 76}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Neutralising antibody responses were measured using a live-virus microneutralisation assay against the B.1.1.7 lineage and a canonical non-B.1.1.7 lineage ( Victoria ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Neutralising antibody responses", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 31}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The efficacy analysis included symptomatic COVID-19 in seronegative participants with a NAAT positive swab more than 14 days after a second dose of vaccine .", "Evidence Elements": {"Participant": [{"term": "symptomatic COVID-19", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 51}, {"term": "seronegative", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 67}, {"term": "NAAT positive swab", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 106}], "Intervention": [{"term": "vaccine", "negation": "affirmed", "UMLS": {}, "start": 148, "end": 155, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Participants were analysed according to vaccine received .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Vaccine efficacy was calculated as 1-relative risk ( ChAdOx1 nCoV-19 vs MenACWY groups ) derived from a robust Poisson regression model .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "ChAdOx1 nCoV-19", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 68, "has_relation": "N/A"}, {"term": "MenACWY", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 79, "has_relation": "N/A"}], "Outcome": [{"term": "Vaccine efficacy", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 16}, {"term": "1-relative risk", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 50}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This study is continuing and is registered with ClinicalTrials.gov , NCT04400838 , and ISRCTN , 15281137 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Participants in efficacy cohorts were recruited between May 31 and Nov 13 , 2020 , and received booster doses between Aug 3 and Dec 30 , 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Of 8534 participants in the primary efficacy cohort , 6636 ( 78 % ) were aged 18-55 years and 5065 ( 59 % ) were female .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Between Oct 1 , 2020 , and Jan 14 , 2021 , 520 participants developed SARS-CoV-2 infection .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": [{"term": "520", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 46}]}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "1466 NAAT positive nose and throat swabs were collected from these participants during the trial .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "NAAT positive nose and throat swabs", "negation": "affirmed", "UMLS": {}, "start": 5, "end": 40}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Of these , 401 swabs from 311 participants were successfully sequenced .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "successfully", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 60}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Laboratory virus neutralisation activity by vaccine-induced antibodies was lower against the B.1.1.7 variant than against the Victoria lineage ( geometric mean ratio 8\u00b79 , 95 % CI 7\u00b72-11\u00b70 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "B.1.1.7 variant", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 108, "has_relation": "N/A"}, {"term": "Victoria lineage", "negation": "affirmed", "UMLS": {}, "start": 126, "end": 142, "has_relation": "N/A"}], "Outcome": [{"term": "Laboratory virus neutralisation activity by vaccine-induced antibodies", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 70}], "Observation": [{"term": "lower", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 80}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "B.1.1.7 variant", "has_relation": "N/A"}, {"term": "Victoria lineage", "has_relation": "N/A"}], "Observation": "lower", "Outcome": "Laboratory virus neutralisation activity by vaccine-induced antibodies", "Count": ""}]}, {"Section": "FINDINGS", "Text": "Clinical vaccine efficacy against symptomatic NAAT positive infection was 70\u00b74 % ( 95 % CI 43\u00b76-84\u00b75 ) for B.1.1.7 and 81\u00b75 % ( 67\u00b79-89\u00b74 ) for non-B.1.1.7 lineages .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "B.1.1.7", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 114, "has_relation": "N/A"}], "Outcome": [{"term": "Clinical vaccine efficacy against symptomatic NAAT positive infection", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 69}], "Observation": [{"term": "70\u00b74 %", "negation": "affirmed", "UMLS": {}, "start": 74, "end": 80}, {"term": "81\u00b75", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 123}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "B.1.1.7", "has_relation": "N/A"}, "Observation": "70\u00b74 %", "Outcome": "Clinical vaccine efficacy against symptomatic NAAT positive infection", "Count": ""}]}, {"Section": "INTERPRETATION", "Text": "ChAdOx1 nCoV-19 showed reduced neutralisation activity against the B.1.1.7 variant compared with a non-B.1.1.7 variant in vitro , but the vaccine showed efficacy against the B.1.1.7 variant of SARS-CoV-2 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "ChAdOx1 nCoV-19", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 15, "has_relation": "N/A"}, {"term": "B.1.1.7 variant", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 82, "has_relation": "N/A"}, {"term": "non-B.1.1.7 variant", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 118, "has_relation": "N/A"}, {"term": "vaccine", "negation": "affirmed", "UMLS": {}, "start": 138, "end": 145, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "B.1.1.7 variant of", "negation": "affirmed", "UMLS": {}, "start": 174, "end": 192, "has_relation": "N/A"}], "Outcome": [{"term": "neutralisation activity", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 54}], "Observation": [{"term": "reduced", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 30}, {"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 153, "end": 161}], "Count": []}, "Evidence Propositions": []}, {"Section": "FUNDING", "Text": "UK Research and Innovation , National Institute for Health Research ( NIHR ) , Coalition for Epidemic Preparedness Innovations , NIHR Oxford Biomedical Research Centre , Thames Valley and South Midlands NIHR Clinical Research Network , and AstraZeneca .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2021 The Author (s ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Elsevier Ltd . This is an Open Access article under the CC BY 4.0 license .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Elsevier Ltd . . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}